Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 April 2005, Vol. 105, No. 7, pp. 2891-2899.
Prepublished online as a Blood First Edition Paper on December 14, 2004; DOI 10.1182/blood-2004-06-2297.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-06-2297v1
105/7/2891    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, L.
Right arrow Articles by Schwaller, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, L.
Right arrow Articles by Schwaller, J.
Related Collections
Right arrow Neoplasia
Right arrow Apoptosis
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-{kappa}B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells

Liza Ho, R. Eric Davis, Béatrice Conne, Richard Chappuis, Margaret Berczy, Paulette Mhawech, Louis M. Staudt, and Juerg Schwaller

From the Department of Clinical Pathology, Geneva University Hospital, Centre Medical Universitaire (CMU), Geneva, Switzerland; and the Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

The most frequently recurring translocations in mucosa-associated lymphoid tissue (MALT) B-cell non-Hodgkin lymphoma, t(11;18)(q21;q21) and t(14;18)(q32; q21), lead to formation of an API2-MALT1 fusion or IgH-mediated MALT1 overexpression. Various approaches have implicated these proteins in nuclear factor {kappa}B (NF-{kappa}B) signaling, but this has not been shown experimentally in human B cells. Immunohistochemistry showed that MALT1 is predominantly expressed in normal and malignant germinal center B cells, corresponding to the differentiation stage of MALT lymphoma. We expressed MALT1 and apoptosis inhibitor-2 API2/MALT1 in human B-cell lymphoma BJAB cells and found both transgenes in membrane lipid rafts along with endogenous MALT1 and 2 binding partners involved in NF-{kappa}B signaling, B-cell lymphoma 10 (BCL10) and CARMA1 (caspase recruitment domain [CARD]-containing membrane-associated guanylate kinase [MAGUK] 1). API2-MALT1 and exogenous MALT1 increased constitutive NF-{kappa}B activity and enhanced I{kappa}B kinase (IKK) activation induced by CD40 stimulation. Both transgenes protected BJAB cells from FAS (CD95)-induced death, consistent with increases in NF-{kappa}B cytoprotective target gene expression, and increased their proliferation rate. Expression of a dominant-negative I{kappa}B{alpha} mutant showed that these survival and proliferative advantages are dependent on elevated constitutive NF-{kappa}B activity. Our findings support a model in which NF-{kappa}B signaling, once activated in a CD40-dependent immune response, is maintained and enhanced through deregulation of MALT1 or formation of an API2-MALT1 fusion.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
J. Dierlamm, E. M. Murga Penas, S. Bentink, S. Wessendorf, H. Berger, M. Hummel, W. Klapper, D. Lenze, A. Rosenwald, E. Haralambieva, et al.
Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma
Haematologica, May 1, 2008; 93(5): 688 - 696.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
G. Sethi, B. Sung, and B. B. Aggarwal
Nuclear Factor-{kappa}B Activation: From Bench to Bedside
Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Noels, G. van Loo, S. Hagens, V. Broeckx, R. Beyaert, P. Marynen, and M. Baens
A Novel TRAF6 Binding Site in MALT1 Defines Distinct Mechanisms of NF-{kappa}B Activation by API2{middle dot}MALT1 Fusions
J. Biol. Chem., April 6, 2007; 282(14): 10180 - 10189.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Van Waes
Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
M-Q Du and J C Atherton
Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.
Gut, June 1, 2006; 55(6): 886 - 893.
[Full Text] [PDF]


Home page
Cancer Res.Home page
M. Baens, S. Fevery, X. Sagaert, H. Noels, S. Hagens, V. Broeckx, A. D. Billiau, C. De Wolf-Peeters, and P. Marynen
Selective Expansion of Marginal Zone B Cells in E{micro}-API2-MALT1 Mice Is Linked to Enhanced I{kappa}B Kinase {gamma} Polyubiquitination.
Cancer Res., May 15, 2006; 66(10): 5270 - 5277.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020